



MIMOSA

MULTISPECTRAL IMAGING IN PERIPHERAL VASCULAR DISEASE (PVD)

Diabetes and Peripheral Vascular Disease (PVD) continue to be a growing epidemic globally, universally placing enormous economic toll on national healthcare systems. With new emerging medical technologies like MIMOSA Pro, however, there is the potential to diagnosis these conditions much earlier before the development of detrimental complications.



The Problem



Approximately 10% of the US population – 8.5 million people – have PAD with over 200 million globally



Medical costs for US management of PAD disease = **\$22 BILLION**



25% of patients with CLI, at one year, 25% have an amputation and 25% cardiovascular mortality



Black ethnicity increases PAD risk by more than double

One of the biggest challenges within PVD management for healthcare systems is the subset of Peripheral Arterial Disease (PAD) patients and those individuals getting access to appropriate vascular assessments. One would hope that most, if not all, PAD patients would have at least an objective noninvasive vascular evaluation before primary amputation occurs, but this is simply not the case in many healthcare settings.

The increasing knowledge that the prognosis of Peripheral Arterial Disease (PAD) and Chronic Limb Ischemia (CLI) is closely correlated to the functional perfusion level of the affected extremity, rather than the macro-vascular structure, may provide better management of these vascular issues. For example, regional foot perfusion imaging may predict wound healing success in addition to becoming a dependable surveillance tool in the management of persons with diabetic foot disease. With this increasing interest and continued understanding of PAD/CLI, vascular surgery moves towards achieving a reduction in persistent ulceration and decreasing the rate of unnecessary amputations for this group of patients.

Multispectral Imaging

MIMOSA Pro is a handheld device that uses near-infrared light to accurately and non-invasively assess tissue health. It can be easily used by a patient or a caregiver, and the images produced will help inform the next steps within patient navigation and management (e.g. you need to see a podiatrist, or a vascular surgeon to help with the blood flow, or you may need more urgent treatment to prevent severe complications like limb loss).



EASE OF USE

Portable and lightweight technology fits easily into your workflow. Both doctors and nurses can use it!

SAFE / NO - TOUCH

Non-invasive and COVID safe with no injectable dyes resulting in zero patient contact.

ACCURATE

Precise visualization of oxygen saturation for faster assessments and healing trajectory predictions.

ANY SKIN TONE

40% Global Population is NOT Caucasian. Built in control for skin melanin content. Overcomes systemic racial bias in healthcare.

ANY HEALTH SETTING

Portability and miniaturization permits utility in any healthcare setting directly by the patients side.

INSIGHT

Tissue health is determined by expert clinicians based on vascularity and oxygenation. Delays or lack of understanding of tissue health can lead to wounds, amputation, or even death.

RISK PROFILE

A means to track and document patient progress to improve clinical outcomes and mitigate risks early.

POINT OF CARE

A portable technology, driving efficiency and accuracy in the diagnostic capabilities of clinicians. The magic of this technology is that its skin pigment, clinical specialty, and care setting agnostic - hence providing equitable access.



There are similar compromised vascular diseases where MIMOSA Pro assessment can make a huge difference. For example, MIMOSA Pro allows for early assessment and diagnosis for patients who have PVD. The deoxyhemoglobin level has been shown to have a positive correlation to the severity of PVD. This emerging assessment and diagnostic tool will have huge impact in the management of patients with compromised vasculature. MIMOSA Pro is going to change the way in which many of these patients are managed.